HRSA-23-065: State Newborn Screening System Priorities Program (NBS Propel)
Closed
This grant is closed. A newer notice from the same program is open now: Women's Initiative for Screening and Health (WISH) (HRSA-27-072). Status: Closes January 8, 2027 (62 days left). It is in our archive of Health Resources and Services Administration notices from 2022.
Health Resources and Services Administration offered grants to state and local governments. It expected to make about 25 awards worth $8.6 million in total. Applications closed on February 13, 2023.
From the official notice on Grants.gov, last changed November 17, 2022. Checked November 7, 2026.
- Total funding$8.6 million
- Expected awards25
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | November 14, 2022 |
|---|---|
| Deadline | February 13, 2023 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include a state or political subdivision of a state, or a consortium of two or more states or political subdivisions of states.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of NBS Propel is to support state/territory NBS programs addressing state/territory-specific challenges; pursue priorities to enhance, improve, and expand the NBS System; improve on NBS timeliness; support implementation of new conditions added to the Recommended Uniform Screening Panel; and increase access to treatment and follow-up activities for individuals and their families with conditions identified through NBS. NBS Propel has two focus areas: Focus Area 1 includes activities related to improving collection of specimens, testing of specimens, and reporting out results, including and improving the timeliness of these activities; and implementing screening for newly added RUSP conditions. Focus Area 2 includes activities related to improving short-term follow-up1 through long-term follow-up2 and helping families understand and navigate the process from confirmation of a diagnosis to treatment, and through follow-up across the lifespan. These activities include expanding access to diagnosis and treatment resources for providers and families of infants with SCID and other NBS disorders with a focus on reaching underserved populations, and empowering families to actively engage at all levels of the newborn screening system.3 Up to 25 recipients will be awarded under NBS Propel to up to 25 different states. Up to three awards will be made to states in each of the 10 HHS/HRSA regions listed below. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont Region 2: New Jersey, New York, Puerto Rico, U.S. Virgin Islands Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas Region 7: Iowa, Kansas, Missouri, Nebraska Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming Region 9: American Samoa, Arizona, California, Federated States of Micronesia, Guam, Hawaii, Marshall Islands, Nevada, Northern Mariana Islands, Palau, Region 10: Alaska, Idaho, Oregon, Washington
Who has won Special Projects of Regional and National Significance grants before
From fiscal 2021 to 2025, Special Projects of Regional and National Significance (93.110) awarded $1.4 billion across 842 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Zero to Three National Center for Infants, Toddlers & Families | District of Columbia | 2 | $54.3 million |
| University Hospitals Cleveland Medical Center | Ohio | 1 | $51.5 million |
| Children's National Medical Center | District of Columbia | 1 | $37.2 million |
| University of North Carolina at Chapel Hill | North Carolina | 8 | $29.1 million |
| American Academy of Pediatrics | Illinois | 8 | $26.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-072, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-23-065 still open?
No. It closed on February 13, 2023. A newer notice is open: HRSA-27-072, closes January 8, 2027 (62 days left).
Who can apply for State Newborn Screening System Priorities Program (NBS Propel)?
Health Resources and Services Administration accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for State Newborn Screening System Priorities Program (NBS Propel)?
Closed February 13, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $8.6 million in total across about 25 awards.
Who has won Special Projects of Regional and National Significance grants before?
The largest recipients over five fiscal years were Zero to Three National Center for Infants, Toddlers & Families, University Hospitals Cleveland Medical Center, Children's National Medical Center. The program made 842 awards worth $1.4 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)